Early engineering approaches to reduce the serum half-life of antibodies and improve therapeutic ratios were based on reduction in antibody size by deletion of constant domains [1, 10, 11].
Overall, IgG anti-agalsidase beta antibodies were detected in 11 of 16 patients, with most experiencing a reduction in antibody titer during the remainder of the study.
However the magnitude of the reduction in antibody responses suggests that EBV may be a contributing factor along with early age of immunisation, persistence of maternal antibody [47] and intense exposure during measles outbreaks due to overcrowding [48].
4-Deoxy-α-Gal derivative 7 showed a significant reduction in antibody recognition.
Furthermore, the MMIHC yielded a 200-fold reduction of antibody consumption, fast immunological reaction, and the ability to examine various biomarkers for cancer chemotherapy in rare tissue samples.
Interestingly, we detected a significant reduction in antibody responses to melanoma with advancing disease stage in our patient cohort (n = 21) (P<0.0001).
Altogether, the results indicate that in Variant FS the carbohydrates and protein form fewer contacts, and that disruption of carbohydrate-pi interactions leads to structural changes and to a significant reduction in antibody stability.
Treatment with immunosuppressants such as rituximab, azathioprine and cyclophosphamide resulted in a marked reduction in antibody levels and relapse rates.
Additionally, the PEGylation resulted in a greater than 10-fold reduction in antibody affinity in comparison to unconjugated protein.
